/
ARVN
$8.29+$0.29 (+3.62%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$516.2M
65M shares
52-week range
$6.06 – $14.51
26% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.29%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-68.71
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3M | $43.0M | $25.9M | $53.6M | $131.4M | $78.5M | $263.4M | $262.6M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $5.2M |
| Gross profit | $14.3M | $43.0M | $25.9M | $53.6M | $131.4M | $78.5M | $263.4M | $257.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.0% |
| R&D | $45.2M | $67.2M | $108.4M | $180.4M | $315.0M | $379.7M | $348.2M | $282.9M |
| Operating income | −$43.8M | −$51.5M | −$120.8M | −$188.4M | −$263.2M | −$401.5M | −$250.2M | −$114.9M |
| EBITDA | −$40.7M | −$68.0M | −$117.6M | −$184.9M | −$253.4M | −$359.7M | −$191.7M | −$75.3M |
| Net income | −$41.5M | −$70.3M | −$119.3M | −$191.0M | −$282.5M | −$367.3M | −$198.9M | −$80.8M |
| Net margin | -289.6% | -163.6% | -460.6% | -356.3% | -215.0% | -467.9% | -75.5% | -30.8% |
| EPS (diluted) | -1.31 | -1.89 | -3.02 | -3.82 | -5.31 | -6.62 | -2.77 | -1.28 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $128M | $-2.83 | $-4.09–$-1.92 | 11 |
| 2027 | $70M | $-3.54 | $-5.01–$-2.34 | 11 |
| 2028 | $69M | $-2.98 | $-4.13–$-1.56 | 9 |
| 2029 | $113M | $-2.24 | $-5.15–$-0.43 | 3 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Arvinas, Inc
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
www.arvinas.com- Employees
- 246
- IPO / List date
- Sep 27, 2018
- HQ
- NEW HAVEN, CT
Held by traders on TradeandTell
No one on the platform currently holds ARVN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 669,655 | $5.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ARVN yet.
